Citigroup Inc. vs Mesoblast Limited — how do they compare? Citigroup Inc. trades at $137.91 (market cap $227.75B), while Mesoblast Limited trades at $16.87 (market cap $2.21B). The key difference: Citigroup Inc. is far larger — about 103.1× Mesoblast Limited's market cap, and Citigroup Inc. pays a 1.97% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| C | MESO | |
|---|---|---|
Market Cap | $227.75B | $2.21B |
Sector | Financials | Technology |
52-Week High | $145.67 | $20.96 |
52-Week Low | $92.59 | $12.88 |
Dividend Yield | 1.97% | — |
Enterprise Value | — | $2.21B |
Signals from Pluang's Aura AI — not financial advice
Citigroup (C) trades at $135.22, up 0.17% with bullish technical signals and strong fundamental momentum. The stock shows robust earnings performance with Q1 and Q2 2026 beats, revenue growth to $85.21B in 2025, and improving profit margins. Analyst consensus is strongly bullish with a $154.38 price target, supported by recent strategic hires and digital transformation initiatives.
Outlook remains positive with revenue projected to reach $91.4B in 2026 and net income margin expanding to 19.52%. Key risks include volatile cash flow patterns and high debt levels. The current valuation at 14.63 P/E offers attractive upside potential relative to analyst targets, though investors should monitor execution of the bank's transformation strategy.
MESO trades at $16.9, up 1.32% on the day, with a bullish technical signal from moving averages. The company reported Ryoncil net revenues of $36 million for the quarter ended June 30, 2026, and achieved its target of 300 patients in a Phase 3 trial for chronic low back pain. Despite strong revenue growth from its commercial launch, fundamentals show a net income margin of -144.33% and negative EBITDA of $80.06 million for 2025, reflecting significant losses amid expansion.
The outlook hinges on commercial execution and regulatory progress, with analyst consensus leaning buy (45% buy ratings). Key risks include high cash burn, dependence on pipeline success, and competitive pressures. Upside potential exists if revenue growth accelerates and losses narrow, but investors face volatility from clinical trial outcomes and funding needs.
Trailing returns across standard periods
Latest headlines on both assets
Citigroup Inc. is a diversified financial services holding company that provides a broad range of financial services to consumer and corporate customers. The Company services include investment banking, retail brokerage, corporate banking, and cash management products and services. Citigroup serves customers globally.
Read more on C →Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →